Mutation Clearance After Chemotherapy and Outcomes in AML
Interview with Timothy Ley, MD, author of Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
Interview with Timothy Ley, MD, author of Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
Interview with Joel G. Ray, MD, MSc, FRCPC, author of Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes
Interview with Vivian S. Lee, MD, PhD, MBA;, author of Implementation of a Value-Driven Outcomes Program to Identify High Variability in Clinical Costs and Outcomes: Association With Reduced Cost and Improved Quality, and Michael E. Porter, PhD, author of From Volume to Value in Health Care: The Work Begins
Interview with Jeffrey L Saver, M.D., author of Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis
Can testosterone gel improve memory, correct anemia, increase bone density or prevent the growth of coronary artery plaque in older men with low testosterone levels? Four new studies in JAMA and JAMA Internal Medicine found improvement in some of these measures.
Articles discussed in this episode:
• Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone
• Association of Testosterone Levels With Anemia in Older Men: A Controlled Clinical Trial
Interview with Freddie C. Hamdy, MD, FRCSEd(Urol), and Jenny L Donovan, PhD, FMedSci, authors of Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Helping Decision Making for Patients and Their Physicians
Interview with Chyke A Doubeni, M.D., F.R.C.S., M.P.H., Task Force member and co-author of Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement
This decision analytical model quantifies the projected gains for deaths prevented or postponed with comprehensive implementation of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) therapy for patients with heart failure with reduced ejection fraction in the United States.